Showing results (11-20 of 160) with videos related to
Sort By:
Pageof 16
Oncotargets and Therapy|June 18, 2016
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerYvonne Le Ang, Joline Sj Lim, Ross A SooLung Cancer (Amsterdam, Netherlands)|February 23, 2016
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancerChee-Seng Tan, Byoung-Chul Cho, Ross A SooTargeted Oncology|February 10, 2018
Treatment of EGFR T790M-Positive Non-Small Cell Lung CancerJoan Rou-En Choo, Chee-Seng Tan, Ross A SooDrug Metabolism Reviews|June 12, 2009
Clinical pharmacology and pharmacogenetics of gemcitabineAndrea Wong, Ross A Soo, Wei-Peng Yong, et al.Therapeutic Advances in Respiratory Disease|April 24, 2015
Best practice in the treatment of advanced squamous cell lung cancerYvonne L E Ang, Hon-Lyn Tan, Ross A SooTherapeutic Advances in Medical Oncology|March 11, 2015
Nivolumab in NSCLC: latest evidence and clinical potentialRaghav Sundar, Byoung-Chul Cho, Julie R Brahmer, et al.Expert Review of Anticancer Therapy|October 18, 2011
Rare subtypes of adenocarcinoma of the lungSai-Hong Ignatius Ou, Tomoya Kawaguchi, Ross A Soo, et al.Lung Cancer (Amsterdam, Netherlands)|March 16, 2013
Personalized therapy on the horizon for squamous cell carcinoma of the lungHan Sang Kim, Tetsuya Mitsudomi, Ross A Soo, et al.Expert Review of Anticancer Therapy|April 17, 2012
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathwaySai-Hong Ignatius Ou, Jackie Tan, Yun Yen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2012
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancerLeow Pay Chin, Ross A Soo, Richie Soong, et al.Pageof 16